IRIS
GRASSADONIA, Antonino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.237
EU - Europa 4.301
AS - Asia 3.614
SA - Sud America 475
AF - Africa 68
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 5
Totale 13.726
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.134
SG - Singapore 1.620
RU - Federazione Russa 1.061
CN - Cina 896
IT - Italia 693
IE - Irlanda 543
VN - Vietnam 402
BR - Brasile 385
SE - Svezia 379
FR - Francia 345
UA - Ucraina 345
GB - Regno Unito 324
DE - Germania 268
TR - Turchia 238
IN - India 133
HK - Hong Kong 92
FI - Finlandia 91
CA - Canada 56
PL - Polonia 49
JP - Giappone 43
BE - Belgio 35
MX - Messico 34
NL - Olanda 34
CZ - Repubblica Ceca 29
IQ - Iraq 29
ZA - Sudafrica 28
BD - Bangladesh 27
AR - Argentina 26
ES - Italia 24
AT - Austria 21
AU - Australia 20
KR - Corea 18
LT - Lituania 16
CO - Colombia 13
EG - Egitto 13
PK - Pakistan 12
SA - Arabia Saudita 12
VE - Venezuela 12
UZ - Uzbekistan 10
ID - Indonesia 9
AE - Emirati Arabi Uniti 8
CL - Cile 8
EC - Ecuador 8
JO - Giordania 8
PT - Portogallo 8
RO - Romania 8
TW - Taiwan 8
PE - Perù 7
CH - Svizzera 6
MA - Marocco 6
MY - Malesia 6
NZ - Nuova Zelanda 6
PY - Paraguay 6
BO - Bolivia 5
DZ - Algeria 5
EU - Europa 5
IL - Israele 5
OM - Oman 5
UY - Uruguay 5
AL - Albania 4
KZ - Kazakistan 4
PH - Filippine 4
TN - Tunisia 4
AZ - Azerbaigian 3
ET - Etiopia 3
GR - Grecia 3
HN - Honduras 3
IR - Iran 3
JM - Giamaica 3
KE - Kenya 3
KW - Kuwait 3
LB - Libano 3
NP - Nepal 3
TT - Trinidad e Tobago 3
BH - Bahrain 2
CI - Costa d'Avorio 2
EE - Estonia 2
GE - Georgia 2
GT - Guatemala 2
LU - Lussemburgo 2
MT - Malta 2
PS - Palestinian Territory 2
SN - Senegal 2
AF - Afghanistan, Repubblica islamica di 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
DK - Danimarca 1
DM - Dominica 1
HU - Ungheria 1
KH - Cambogia 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
MN - Mongolia 1
NI - Nicaragua 1
RS - Serbia 1
SC - Seychelles 1
SI - Slovenia 1
TH - Thailandia 1
Totale 13.726
Salva come PNG Salva come JPEG
Città #
Singapore 1.253
Chandler 657
San Jose 590
Dublin 531
Jacksonville 436
Ashburn 420
Dallas 265
Beijing 253
Princeton 203
Los Angeles 166
Southend 166
The Dalles 145
Izmir 134
Santa Clara 129
Nanjing 128
Ho Chi Minh City 124
New York 97
Chieti 94
Pescara 92
Ann Arbor 84
Dearborn 84
Hong Kong 84
Wilmington 84
Altamura 83
Hanoi 77
Munich 76
Boardman 67
Cambridge 62
Tongling 60
Buffalo 49
Moscow 49
Dong Ket 40
Redondo Beach 39
São Paulo 39
Nanchang 37
Tokyo 37
Rome 34
Council Bluffs 33
Brussels 32
Nuremberg 32
Orem 31
London 29
Denver 28
Frankfurt am Main 28
Washington 28
Woodbridge 28
Hefei 27
Amsterdam 26
Brooklyn 26
Milan 26
Atlanta 24
Da Nang 24
Montreal 24
Warsaw 24
Brno 23
Chicago 22
Hebei 22
Kunming 21
Shenyang 21
Stockholm 20
Tianjin 20
Boston 19
Houston 19
Johannesburg 19
Norwalk 19
Chennai 18
Jiaxing 18
Kraków 18
Helsinki 15
Poplar 15
Seoul 15
Falls Church 14
Turku 14
Changsha 13
Lappeenranta 13
Manchester 13
Phoenix 13
Rio de Janeiro 13
City of London 12
Ancona 11
Grevenbroich 11
Hyderabad 11
Melbourne 11
Mexico City 11
Vienna 11
Cairo 10
Haiphong 10
Hangzhou 10
Seattle 10
Baghdad 9
Guangzhou 9
Ninh Bình 9
Tashkent 9
Toronto 9
Amman 8
Augusta 8
Belo Horizonte 8
Charlotte 8
Guarulhos 8
Istanbul 8
Totale 8.066
Salva come PNG Salva come JPEG
Nome #
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer 835
90K (Mac-2 BP) and galectins in tumor progression and metastasis. 181
Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation 173
Impact of BMI on clinical outcome in advanced cancer patients treated with anti‑PD‑1 Immune checkpoint inhibitors: a preliminary analysis 172
A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience 171
The Role of the Environment and Type of Exercise on Acute Adrenal Modulation and Perceived Distress of Breast Cancer Survivors Practising Light-Intensity Physical Exercise 171
Breast cancer "tailored follow-up" in Italian oncology units: A web-based survey 170
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer. 164
Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients 163
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting 157
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 156
Gli analoghi sintetici delle glicoamine come potenziali nuovi farmaci nella prevenzione delle metastasi 156
A Case of Stage I Vulvar Squamous Cell Carcinoma with Early Relapse and Rapid Disease Progression 155
Occupational allergy: is there a role for nanoparticles? 154
Exosomes as pleiotropic players in pancreatic cancer 153
90k is a serum marker of poor-prognosis in non-hodgkins-lymphoma patients. 149
Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin 149
High Blood Concentration of Leukocyte-Derived Extracellular Vesicles Is Predictive of Favorable Clinical Outcomes in Patients with Pancreatic Cancer: Results from a Multicenter Prospective Study 148
The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer 148
Analisi dello stato mutazionale di K-RAS: un nuovo strumento per la selezione dei pazienti candidati a terapia con anticorpi anti-EGFR 147
Blood Circulating CD133+ Extracellular Vesicles Predict Clinical Outcomes in Patients with Metastatic Colorectal Cancer 146
A novel serum test using interferon for early detection of tumor reccurrence in cancer patients after radical surgery. 146
The 90K protein increases major histocompatibility complex class I expression and is regulated by hormones, gamma-interferon, and double-strand polynucleotides. 146
Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials 146
New Targets for Therapy in Pancreatic Cancer 144
An Epigenetic Approach to Pancreatic Cancer Treatment: the Prospective Role of Histone Deacetylase Inhibitors 142
High expression of 90K (Mac-2 BP) is associated with poor survival in node-negative breast cancer patients not receiving adjuvant systemic therapies 141
Glicomimetici quali potenziali nuovi farmaci per la prevenzione delle metastasi. 140
A phase I study of 5-day continuous venous infusion of carboplatin (CBDCA) at circadian rhythm-modulated rate 136
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice. 135
Resveratrol inhibits sodium/iodide symporter gene expression and function in rat thyroid cells 134
Upstream stimulatory factor regulates constitutive expression and hormonal suppression of the 90K (Mac-2BP) protein. 131
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 131
Inhibition of tumor growth and angiogenesis by SP-2, an anti-LGALS3BP antibody 130
BIOLOGICAL INDICATORS OF PROGNOSIS IN HUMAN CANCER: AN EMERGING ROLE FOR LECTIN GALACTOSIDE-BINDING SOLUBLE 3-BINDING PROTEIN (LGALS3BP) 129
Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer 128
Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer 127
Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial. 127
Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 126
TGF-β-1 increases 90K tumor associated antigen gene expression by increasing upstream regulatory factor binding to the minimal promoter. 123
Principali effetti collaterali delle terapie mediche 122
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 122
Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study 121
The flavonoid quercetin inhibits thyroid-restricted genes expression and thyroid function. 120
Do cut-off values of lymph node ratio and presence of perineural invasion affect survival in breast cancer patients with pathologic N3a lymph node stage? Reply to Kadri Altundag 120
Corrigendum to "Circulating Cancer Stem Cell-Derived Extracellular Vesicles as a Novel Biomarker for Clinical Outcome Evaluation" 120
Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression 119
Drug repurposing, an attractive strategy in pancreatic cancer treatment: Preclinical and clinical updates 117
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE study 116
Detection of Germline Mutations in a Cohort of 250 Relatives of Mutation Carriers in Multigene Panel: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 115
Tumor-derived microvesicles: The metastasomes. 115
Identification of Subgroups of Early Breast Cancer Patients at High Risk of Nonadherence to Adjuvant Hormone Therapy: Results of an Italian Survey 115
Long-term outcome of breast cancer patients with pathologic N3a lymph node stage 114
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 114
Prognostic value of gender and primary tumor location in metastatic colon cancer 114
Exploring the Immunomodulatory Potential of Pancreatic Cancer-Derived Extracellular Vesicles through Proteomic and Functional Analyses 113
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer 112
Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies? 111
LGALS3BP, A TUMOR-ASSOCIATED ANTIGEN, UPREGULATES VEGF IN HUMAN BREAST CANCER: POSSIBLE IMPLICATIONS IN ANGIOGENESIS 111
La stimolazione dinamica con IFN-α per la diagnosi precoce di ripresa di malattia in pazienti NED 110
Circadian timing of chemotherapeutic agents:a phase II study of 5-fluoro-2-deoxyuridine in gastrointestinal cancer and renal cell carcinoma 110
Alectinib induced regression of renal and hepatic cysts caused by crizotinib 110
Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. 109
Regolazione, funzione ed espressione genica dell’antigene tumore-associato 90K/AC-2 BP 107
Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer 106
Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: A systematic review 106
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab 106
Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: A retrospective multicenter study 106
Relationships between daily physical activity combinations and psychophysical health status of Italian breast cancer survivors 106
Oral etoposide and platinum derivates in the treatment of metastatic Merkel cell carcinoma: report of three cases 103
Preoperative dose-dense sequential chemotherapy of epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with breast cancer 102
Thyroglobulin autoregulation of thyroid-specific gene expression and follicular function 102
Possible role of thymidylate synthase level in hunan colorectal carcinoma: a new prognostic factor? 101
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 101
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies 99
Phenotypic and proteomic analysis identifies hallmarks of blood circulating extracellular vesicles in NSCLC responders to immune checkpoint inhibitors 99
Neoadjuvant Chemotherapy for Surgically Staged IIIA N2 Non-Small Cell Lung Cancer (NSCLC) in the Elderly 98
Thymidylate synthase level and DNA-ploidy pattern as possible prognostic factors in human colorectal cancer: a preliminary study 98
Thyroglobulin regulates follicular function and heterogeneity by suppressing thyroid-specific gene expression. 98
Neoadjuvant Sequential Docetaxel Followed by High-Dose Epirubicin in Combination With Cyclophosphamide Administered Concurrently With Trastuzumab. The DECT Trial 98
Flexibility and Strength Effects of Adapted Nordic Walking and Myofascial Exercises Practice in Breast Cancer Survivors and Analysis of Differences 96
Pretreatment neutrophil-lymphocyte ratio (NLR) predicted overall survival (OS) for metastatic melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) patients who received monotherapy with immune checkpoint inhibitor as ipilimumab, nivolumab and pembrolizumab 95
Effect of taxanes following anthracyclines on pathologic complete response (pCR) in patients with triple-negative breast cancer (TNBC) receiving primary systemic therapy (PST). 94
The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective 94
Impact of Body Mass Index (BMI) on outcome of metastatic breast cancer (MBC) patients (pts) treated with Eribulin in a real-world population: a multicenter retrospective study 93
Prognostic value of a novel interferon-inducible 90K tumor antigen 92
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients 91
The Crucial Role of Hereditary Cancer Panel Testing in Unaffected Individuals with a Strong Family History of Cancer: A Retrospective Study of a Cohort of 103 Healthy Subjects 90
FPSE-HPLC-DAD metod for the quantification of anticancer drugs in human whole blood, plasma and urine 90
Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study 90
Thyroglobulin repression of thyroid transcription factor 1 (TTF-1) gene expression is mediated by decreased DNA binding of nuclear factor I proteins which control constitutive TTF-1 expression 89
Prognostic relevance of DNA damage and repair biomarkers in elderly patients with hormone-receptor-positive breast cancer treated with neoadjuvant hormone therapy: evidence from the real-world setting 89
Infusione cronomodulata di farmaci in oncologia 86
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer 85
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter study. 85
Current challenges in HER2-positive breast cancer 83
Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: An insight from clinical practice 83
Whole breast radiotherapy in cN0 early breast cancer patients with pathological sentinel lymph nodes (pN1mic, pN1a) without axillary dissection: preliminary results of the observational LISEN trial 83
Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting 81
The Impact of the Hippo Pathway and Cell Metabolism on Pathological Complete Response in Locally Advanced Her2+ Breast Cancer: The TRISKELE Multicenter Prospective Study 78
Totale 12.733
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.139
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.139
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021164 0 0 0 0 0 0 0 0 0 61 40 63
2021/2022557 19 15 5 118 34 32 15 46 33 15 62 163
2022/20231.842 143 236 160 191 190 329 98 155 210 16 70 44
2023/20241.029 86 31 66 44 64 329 173 30 41 33 25 107
2024/20252.361 137 390 324 109 61 118 116 125 223 176 257 325
2025/20265.360 400 199 498 553 543 330 978 293 1.204 362 0 0
Totale 14.243